Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
- Sponsor
- Medical University of Vienna
- Study ID
- NCT06865365
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Obesity, Adolescent
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions — DRUGLiraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
- Dietologic measures and lifestyle optimization for weight loss — BEHAVIORALall subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
Study Details
The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet. The investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Mar 2025
- Primary completion
- Feb 1, 2027
- Completion
- Feb 1, 2028
Study Design
- Enrollment
- 72 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Group A - Control Group with only dietological measuresPatients seeking bariatricsurgery will recieve the standard dietological measures to prepare for bariatric surgery for 6 months
- Experimental: Group B - Intervention with additional LiraglutidePatients seeking bariatricsurgery will recieve the standard dietological measures and additional Liraglutide to prepare for bariatric surgery for 6 months
Primary Outcome Measure
% total weight loss [ Time Frame: body weight and bmi will be assessed immediately when admission to the study is done as reference value and at at time of operation, which is 6 months after admission to the study, as outcome value ]
Central Contacts
- Lea Pedarnig, MD0043014040056210
- Moritz Felsenreich, Ap.Prof.Priv.-Doz.DDr.0043014040056210
Related Studies
- Pain and Weight Treatment: Development and Trial of PAWRecruiting · Connecticut Children's Medical Center · Hartford, Connecticut
- Oxytocin for Weight Loss in AdolescentsPHASE2 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Wakaya: Rising Up for Choctaw Youth HealthRecruiting · University of Washington · Durant, Oklahoma
- Health Without Barriers/Salud Sin Barreras- Northern ColoradoRecruiting · Colorado State University · Fort Collins, Colorado